Source:http://linkedlifedata.com/resource/pubmed/id/20494667
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
11
|
pubmed:dateCreated |
2010-5-24
|
pubmed:abstractText |
Carcinoid heart disease is a rare disease, and its prevalence is uncertain. The aim of the present prospective study was to assess the prevalence of carcinoid heart disease using annual echocardiographic follow-up. We studied 80 consecutive patients presenting with histologically proven digestive endocrine tumor and carcinoid syndrome. All patients underwent annual conventional transthoracic echocardiographic studies and measurement of biologic carcinoid markers. Right- and left-sided carcinoid heart disease and the score of the severity of carcinoid heart disease were systematically assessed. At baseline, the prevalence of right- and left-sided carcinoid heart disease was 33% and 8%, respectively. At the end of follow-up, the corresponding prevalence was 53% and 21%. The correlations were strong between urinary 5-hydroxyindoleacetic acid (5-HIAA) and the right-sided carcinoid heart disease score (r = 0.75, p <0.0001), between urinary 5-HIAA and the left-sided carcinoid heart disease score (r = 0.83, p = 0.001), and between urinary 5-HIAA and the overall carcinoid heart disease score (r = 0.84, p <0.0001). All patients with > or =3 years of carcinoid syndrome and increased level of urinary 5-HIAA presented with echocardiographic evidence of valve disease on routine monitoring. In conclusion, the prevalence of carcinoid heart disease remained high and increased during follow-up. Carcinoid heart disease progresses over time, highlighting the need for echocardiographic follow-up once carcinoid syndrome has been diagnosed.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
1879-1913
|
pubmed:author | |
pubmed:copyrightInfo |
Copyright 2010 Elsevier Inc. All rights reserved.
|
pubmed:issnType |
Electronic
|
pubmed:day |
1
|
pubmed:volume |
105
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1588-91
|
pubmed:meshHeading |
pubmed-meshheading:20494667-Aged,
pubmed-meshheading:20494667-Biological Markers,
pubmed-meshheading:20494667-Carcinoid Heart Disease,
pubmed-meshheading:20494667-Echocardiography,
pubmed-meshheading:20494667-Female,
pubmed-meshheading:20494667-Follow-Up Studies,
pubmed-meshheading:20494667-Heart Neoplasms,
pubmed-meshheading:20494667-Humans,
pubmed-meshheading:20494667-Hydroxyindoleacetic Acid,
pubmed-meshheading:20494667-Male,
pubmed-meshheading:20494667-Middle Aged,
pubmed-meshheading:20494667-Paris,
pubmed-meshheading:20494667-Prevalence,
pubmed-meshheading:20494667-Prospective Studies,
pubmed-meshheading:20494667-Severity of Illness Index
|
pubmed:year |
2010
|
pubmed:articleTitle |
Echocardiographic follow-up of treated patients with carcinoid syndrome.
|
pubmed:affiliation |
Department of Cardiology, Université de Versailles-Saint Quentin, Hôpital Ambroise Paré, Assistance Publique-Hôpitaux de Paris, Boulogne, France. nicolas.mansencal@apr.aphp.fr
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|